Regenxbio Inc
RGNX8.305USD
+0.115+1.40%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
416.22MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Regenxbio Inc Unternehmen
REGENXBIO Inc. is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address genetic diseases. The Company is focused on its internal development pipeline in three areas: retinal, neuromuscular and neurodegenerative diseases. Its investigational AAV therapeutics include ABBV-RGX-314, RGX-202 and RGX-121. It is developing ABBV-RGX-314 in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision. It is developing RGX-202 to treat Duchenne muscular dystrophy (Duchenne). The Company is developing RGX-121 to treat Mucopolysaccharidosis type II (MPS II), a progressive, neurodegenerative lysosomal storage disorder.
Unternehmensinformationen
BörsenkürzelRGNX
Name des UnternehmensRegenxbio Inc
IPO-datumSep 17, 2015
CEOMr. Curran M. Simpson
Anzahl der mitarbeiter353
WertpapierartOrdinary Share
GeschäftsjahresendeSep 17
Addresse9804 Medical Center Drive
StadtROCKVILLE
BörseNASDAQ Global Select Consolidated
LandUnited States of America
Postleitzahl20850
Telefon12405528181
Websitehttps://regenxbio.com/
BörsenkürzelRGNX
IPO-datumSep 17, 2015
CEOMr. Curran M. Simpson
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Mitchell Chan
Mr. Mitchell Chan
Chief Financial Officer, Executive Vice President, Principal Accounting Officer
Chief Financial Officer, Executive Vice President, Principal Accounting Officer
58.87K
--
Dr. Olivier Danos, Ph.D.
Dr. Olivier Danos, Ph.D.
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
58.37K
-55.17%
Mr. Curran M. Simpson
Mr. Curran M. Simpson
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
31.47K
-13.00%
Ms. Jennifer L. Zachary
Ms. Jennifer L. Zachary
Independent Director
Independent Director
20.06K
+63.21%
Mr. Daniel Tasse
Mr. Daniel Tasse
Lead Independent Director
Lead Independent Director
19.05K
+68.83%
Mr. George V. Migausky
Mr. George V. Migausky
Independent Director
Independent Director
19.05K
+68.83%
Mr. Craig Malzahn
Mr. Craig Malzahn
Executive Vice President - Product Development, Chief Technology Officer
Executive Vice President - Product Development, Chief Technology Officer
17.82K
--
Mr. Allan M. Fox, J.D.
Mr. Allan M. Fox, J.D.
Director
Director
--
--
Dr. David C. (Dave) Stump, M.D.
Dr. David C. (Dave) Stump, M.D.
Independent Director
Independent Director
--
--
Dr. A. N. (Jerry) Karabelas, Ph.D.
Dr. A. N. (Jerry) Karabelas, Ph.D.
Independent Director
Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Mitchell Chan
Mr. Mitchell Chan
Chief Financial Officer, Executive Vice President, Principal Accounting Officer
Chief Financial Officer, Executive Vice President, Principal Accounting Officer
58.87K
--
Dr. Olivier Danos, Ph.D.
Dr. Olivier Danos, Ph.D.
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
58.37K
-55.17%
Mr. Curran M. Simpson
Mr. Curran M. Simpson
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
31.47K
-13.00%
Ms. Jennifer L. Zachary
Ms. Jennifer L. Zachary
Independent Director
Independent Director
20.06K
+63.21%
Mr. Daniel Tasse
Mr. Daniel Tasse
Lead Independent Director
Lead Independent Director
19.05K
+68.83%
Mr. George V. Migausky
Mr. George V. Migausky
Independent Director
Independent Director
19.05K
+68.83%
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Sat, May 17
Aktualisiert: Sat, May 17
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Redmile Group, LLC
9.52%
BlackRock Institutional Trust Company, N.A.
7.77%
The Vanguard Group, Inc.
6.89%
JP Morgan Asset Management
5.85%
Fox (Allan Mark)
5.76%
Other
64.21%
Aktionäre
Aktionäre
Anteil
Redmile Group, LLC
9.52%
BlackRock Institutional Trust Company, N.A.
7.77%
The Vanguard Group, Inc.
6.89%
JP Morgan Asset Management
5.85%
Fox (Allan Mark)
5.76%
Other
64.21%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor/Hedge Fund
29.45%
Investment Advisor
29.40%
Hedge Fund
17.30%
Research Firm
8.25%
Individual Investor
7.69%
Sovereign Wealth Fund
2.96%
Pension Fund
0.32%
Bank and Trust
0.25%
Family Office
0.10%
Other
4.27%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
421
48.24M
95.74%
-3.52M
2025Q1
446
48.46M
96.35%
-3.90M
2024Q4
444
48.16M
97.22%
-4.82M
2024Q3
444
49.64M
100.43%
-4.45M
2024Q2
437
49.30M
99.98%
-3.20M
2024Q1
451
48.23M
99.21%
+414.63K
2023Q4
436
43.62M
98.84%
-7.14M
2023Q3
439
43.73M
99.56%
-6.26M
2023Q2
439
43.86M
100.57%
-5.31M
2023Q1
456
44.07M
101.46%
-1.49M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Redmile Group, LLC
4.79M
9.52%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
3.92M
7.77%
+48.66K
+1.26%
Mar 31, 2025
The Vanguard Group, Inc.
3.47M
6.89%
+495.83K
+16.65%
Mar 31, 2025
JP Morgan Asset Management
2.95M
5.85%
+36.88K
+1.27%
Mar 31, 2025
Fox (Allan Mark)
2.90M
5.76%
+7.77K
+0.27%
May 30, 2025
Morgan Stanley & Co. LLC
1.57M
3.11%
+45.10K
+2.96%
Mar 31, 2025
Balyasny Asset Management LP
1.40M
2.78%
+211.40K
+17.81%
Mar 31, 2025
Dimensional Fund Advisors, L.P.
1.15M
2.28%
-23.70K
-2.02%
Mar 31, 2025
Geode Capital Management, L.L.C.
1.11M
2.2%
+12.72K
+1.16%
Mar 31, 2025
BlackRock Financial Management, Inc.
1.09M
2.17%
-19.59K
-1.76%
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Aug 2
Aktualisiert: Sat, Aug 2
Name
Anteil
WisdomTree BioRevolution Fund
1.81%
iShares Neuroscience and Healthcare ETF
0.92%
Virtus LifeSci Biotech Clinical Trials ETF
0.72%
Global X Genomics & Biotechnology ETF
0.48%
JPMorgan Fundamental Data Science Small Core ETF
0.34%
ALPS Medical Breakthroughs ETF
0.28%
SPDR S&P Biotech ETF
0.13%
iShares Health Innovation Active ETF
0.08%
Direxion Daily S&P Biotech Bull 3X Shares
0.07%
Fidelity Enhanced Small Cap ETF
0.07%
Mehr Anzeigen
WisdomTree BioRevolution Fund
Anteil1.81%
iShares Neuroscience and Healthcare ETF
Anteil0.92%
Virtus LifeSci Biotech Clinical Trials ETF
Anteil0.72%
Global X Genomics & Biotechnology ETF
Anteil0.48%
JPMorgan Fundamental Data Science Small Core ETF
Anteil0.34%
ALPS Medical Breakthroughs ETF
Anteil0.28%
SPDR S&P Biotech ETF
Anteil0.13%
iShares Health Innovation Active ETF
Anteil0.08%
Direxion Daily S&P Biotech Bull 3X Shares
Anteil0.07%
Fidelity Enhanced Small Cap ETF
Anteil0.07%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
